A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
Study sponsor: NeuroSense Therapeutics Ltd. · NRSN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-11-02Actual
Enrollment · participants69Actual
Source updated2025-09-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.